Rejdak Robert, Szkaradek Małgorzata, Grieb Paweł, Jünemann Anselm G M
Department of Ophthalmology, Medical University of Lublin, Lublin, Poland.
Klin Oczna. 2011;113(10-12):376-8.
Age-related macular degeneration (AMD) is the leading cause of blindness in the industrialized world. The most severe form of this disease is exudative AMD. It accounts for 10% of cases of AMD and is responsible for approximately 90% cases of severe vision loss due to AMD. Anti-vascular endothelial growth factor (VEGF) therapy changed the standard-of-care for this blinding disease. This article presents one promising new drug for the treatment of exudative AMD--VEGF Trap-Eye.
年龄相关性黄斑变性（AMD）是工业化国家失明的主要原因。这种疾病最严重的形式是渗出性AMD。它占AMD病例的10%，约占AMD导致严重视力丧失病例的90%。抗血管内皮生长因子（VEGF）疗法改变了这种致盲疾病的治疗标准。本文介绍了一种治疗渗出性AMD的有前景的新药——VEGF Trap-Eye。
